Theralase Technologies Inc. V.TLT

Please Clarify for me ! Does this include non optimized ?

[Oden6570]

If this does include the original non optimized treated patients , What would the TR and CR rates be ? Regardless stellar results IMHO, The worst of the worst  NMIBC patients facing Bladder Removal or potential death and now Cancer free after 1 TLT Treatment , Only In Canada you say ! On the Vulture exchange were all companies and retail investors are raped and pilleged by scalliwags with impunity , how do we fight back ?

I mean holy cow Batman why the Bleep is this company's share price so low ? # POW , # BAM , # WHOP , No Idea Robin  back to the Bat Cave now gather all the loose change we can ! At some point soon the tide will change ! I have decided to reduce Alfords pay and buy more shares at this price point !

Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, "The interim clinical data of Study II to date has proven to be world-class. Study II has demonstrated an ability to destroy urothelial cell carcinoma in a patient's bladder for a total response of 69% and a duration of that total response of 43%, for patients treated with the optimized Study Procedure. The primary benefits of the Theralase® technology versus competitive technologies are the high efficacy rates (patients achieve a CR in approximately 60% of the cases after only one Study Procedure), high duration of response and high safety margin (no SAEs directly associated with the Study Drug or Study Device); therefore, the Theralase® technology presents a safe, effective alternative therapy for patients, who are at risk of having their bladder removed."

THERALASE TECHNOLOGIES INC. (:TLT) Theralase(R) Release's 4Q2023 Interim Financial Statements (webdisclosure.com)